Data on HIV/AIDS cancer discussed by researchers at University of California
2009 JUL 13 - (NewsRx.com) -- "The results of many laboratory studies suggest that amphetamine use may lead to altered immune function and cytokine expression, both of which are implicated in HIV-related lymphomagenesis. We examined the hypothesis that use of amphetamines modifies risk of non-Hodgkin lymphoma (NHL) in HIV-infected men in the Multicenter AIDS Cohort Study," scientists in the United States report. "Data on amphetamine use were collected every six months during the follow-up period between 1984 and 2002. A total of 171 NHL cases were diagnosed from the 19,250 person-years accrued. Multivariable Cox models were used to estimate the effects of baseline exposures, time-varying recent exposures, and three years lagged exposures on risk of NHL adjusting for potential confounders such as demographics, use of other substances, and risky sexual behaviors. We found that weekly or more frequent use of amphetamines was associated with an increased risk of NHL, with hazard ratios of 1.75 (95% CI = 0.81-3.77) for use at baseline, 4.73 (1.41-15.81) for recent use, and 3.05 (1.19-7.82) for three years prior use. Similar associations were observed when we separately examined systemic NHL and diffuse large B-cell lymphoma," wrote C. Chao and colleagues, University of California. The researchers concluded: "Given these observations, the impact of amphetamines on lymphomagenesis among HIV-infected populations should be assessed more thoroughly.." Chao and colleagues published their study in Cancer Causes & Control (Recreational amphetamine use and risk of HIV-related non-Hodgkin lymphoma. Cancer Causes & Control, 2009;20(5):509-516). For more information, contact Z.F. Zhang, University of California, Dept. of Epidemiology, 71-225 CHS, 650 Charles E Young Dr. S, POB 951772, Los Angeles, CA 90095, USA. Publisher contact information for the journal Cancer Causes & Control is: Springer, Van Godewijckstraat 30, 3311 Gz Dordrecht, Netherlands. Keywords: United States, Los Angeles, HIV/AIDS Cancer, AIDS, Acquired Immunodeficiency Syndrome, Adrenergic Agent, Adrenergic Uptake Inhibitor, Amphetamine, Central Nervous System Stimulant, Clinical Trial Research, Dopamine, HIV, Hematology, Human Immunodeficiency Virus Cancer, Non-Hodgkin Lymphoma, Oncology, Virology, University of California. This article was prepared by AIDS Weekly editors from staff and other reports. Copyright 2009, AIDS Weekly via NewsRx.com.
|
